CCB02

• Description :

  CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC50 of 689 nM, and shows potent anti-tumor activity. CCB02 shows no inhibition on the cell cycle- and centrosome-related kinases, or the phosphorylation status of Aurora A, Plk1, Plk2, CDK2, and CHK1[1].

• Product Name Alternative :

  (-)-Pindolol; (S)-(-)-Pindolol; S-Pindolol, ONO1109, ONO1101 (hydrochloride)

• UNSPSC :

  12352005

• Target :

  Microtubule/Tubulin

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Cytoskeleton

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/CCB02.html

• Purity :

  99.93

• Solubility :

  DMSO : 25 mg/mL (ultrasonic)

• Smiles :

  N#CC1=C(OC)N=CC2=CC3=CC=CC=C3N=C12

• Molecular Formula :

  C14H9N3O

• Molecular Weight :

  235.24

• References & Citations :

  [1]Mariappan A, et al. Inhibition of CPAP-tubulin interaction prevents proliferation of centrosome-amplified cancer cells. EMBO J. 2019 Jan 15;38 (2) . pii: e99876.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2100864-57-9]